DeepMed Research

DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa

Phase 2

Active, not recruiting

Conditions: Breast Cancer

Interventions: Drug: Trastuzumab
Drug: Pertuzumab
Drug: Paclitaxel
Drug: Doxorubicin
Drug: Cyclophosphamide
Procedure: Mastectomy
Radiation: Radiation Therapy

First Posted Date: 2013-02-21

Last Posted Date: 2025-02-26

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 23

Registration Number: NCT01796197

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
University of Michigan, Ann Arbor, Michigan, United States

BKM120 For Triple Negative Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: BKM120

First Posted Date: 2013-02-13

Last Posted Date: 2019-01-23

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 50

Registration Number: NCT01790932

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

and more 1 locations

A Phase II Trial of Regadenoson in Sickle Cell Anemia

Phase 2

Completed

Conditions: Sickle Cell Anemia

Interventions: Drug: Placebo
Drug: Regadenoson

First Posted Date: 2013-02-11

Last Posted Date: 2018-02-07

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 100

Registration Number: NCT01788631

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸
Baylor College of Medicine, Houston, Texas, United States
🇺🇸
Duke University, Durham, North Carolina, United States

and more 9 locations

Serious Illness Communication Project

Not Applicable

Completed

Conditions: End of Life Care
Cancer

Interventions: Behavioral: Training

First Posted Date: 2013-02-08

Last Posted Date: 2019-01-22

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 994

Registration Number: NCT01786811

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Safety Study of Afatinib and Postoperative Radiation Therapy to Treat Head and Neck Cancer

Phase 1

Completed

Conditions: Squamous Cell Carcinoma of the Head and Neck

Interventions: Drug: Afatinib
Radiation: Radiation Therapy
Drug: Docetaxel

First Posted Date: 2013-02-05

Last Posted Date: 2025-05-01

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 29

Registration Number: NCT01783587

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Mount Sinai Medical Center/Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors

Phase 2

Completed

Conditions: Carcinoid Tumor

Interventions: Drug: Ziv-aflibercept

First Posted Date: 2013-02-01

Last Posted Date: 2023-08-14

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 19

Registration Number: NCT01782443

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

GVAX vs. Placebo for MDS/AML After Allo HSCT

Phase 2

Terminated

Conditions: Myelodysplastic Syndrome
Acute Myeloid Leukemia
Chronic Myelomonocytic Leukemia

Interventions: Biological: GVAX
Biological: Placebo Vaccine
Procedure: Allogeneic Hematopoietic Stem Cell Transplant
Drug: Busulfan
Drug: Fludarabine
Drug: Tacrolimus
Drug: Methotrexate

First Posted Date: 2013-01-23

Last Posted Date: 2022-07-18

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 123

Registration Number: NCT01773395

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 1 locations

Ponatinib for Squamous Cell Lung and Head and Neck Cancers

Phase 2

Terminated

Conditions: Non-Small Cell Lung Cancer, Head and Neck Cancer

Interventions: Drug: ponatinib

First Posted Date: 2013-01-07

Last Posted Date: 2014-12-23

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 3

Registration Number: NCT01761747

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

and more 1 locations

Standard of Care vs. Bortezomib in Graft-Versus Host Disease After Hematopoietic Stem Cell Transplant

Phase 2

Completed

Conditions: Graft Versus Host Disease

Interventions: Drug: Tacrolimus
Drug: Methotrexate
Drug: Bortezomib
Drug: Sirolimus

First Posted Date: 2012-12-21

Last Posted Date: 2017-07-18

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 138

Registration Number: NCT01754389

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Insitute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

and more 1 locations

INHERIT EGFR - Studying Germline EGFR Mutations

Active, not recruiting

Conditions: Lung Cancer

First Posted Date: 2012-12-21

Last Posted Date: 2025-04-17

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 121

Registration Number: NCT01754025

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy